Advances in the diagnosis, and use of radiation therapy and chemotherapy, have greatly improved the survival of patients with Hodgkin's disease over the past two to three decades. Approximately 70% of all patients can now be cured, and for patients with early disease (stage I and II) this figure approaches 95% (Gospodarowicz et al, 1992a; Hoppe, 1990) . Increasing numbers of patients are surviving and are at risk for late complications of treatment. Optimization of primary therapy should include consideration of potential late toxicities in addition to the more immediate goals of disease eradication and reduction in acute morbidity. Although individual late effects following treatment for all stages of HD have been documented by many centres (Hoppe, 1990; Cosset et al, 1991a; Boivin et al, 1992; Henry-Amar, 1992; Valagussa et al, 1992; van Tulder et al 1994; Mauch et al, 1995) , this study attempts to determine comprehensively the late effects following treatment for early stage HD at our centre.
Excellent results of treatment have been achieved using different treatment strategies in various countries. As well as treatment results, it is essential to report late complications as a means of selecting treatments with the best chance of cure and the least risk of toxicity. We report our experience with late morbidity associated with treatment of early stage HD at the Princess Margaret Hospital (PMH) .
The study population for this report comprised all patients with stage I and II Hodgkin's disease treated at the PMH between 1973 and 1984. The total number of patients was 611 (332 men, 279 women) with a median age at diagnosis of 31 years (range 17-90) . Patients were staged according to the Ann Arbor classification based on physical examination, complete blood count (CBC), sedimentation rate, liver function tests, chest radiograph and bipedal lymphography, supplemented after 1980 by computerized tomography (CT) scan of abdomen and pelvis. Only 38 (6.2%) patients had staging laparotomy. The choice of treatment was determined according to prognostic factors as reported previously (Sutcliffe et al, 1985; Gospodarowicz et al, 1992a, b) . The extent of disease and treatment, including stage, histology, treatment modality, extent of radiation and chemotherapy, is shown in Table 1 . Extended field radiation was delivered to 245 patients (41.2%) and consisted of a mantle field followed by upper abdominal irradiation to the para-aortic lymph nodes and spleen after a 4-week interval. A total of 246 patients (41.5%) received mantle radiation or inverted Y radiation for infradiaphragmatic disease, and 103 patients (17.3%) received involved field radiation only. Mantle fields were treated with equally weighted anterior and posterior parallel pair technique with attenuation to compensate for contour irregularity. A total of 230 patients (37.6%) were treated with one field a day. The usual radiation dose and fractionation schedule was 3500 cGy given in 20 daily treatments over 28 days, delivered by a cobalt unit with extended SSD. A total of 357 (60.1%) patients received 3500 cGy in 20 fractions. Pneumococcal vaccine or prophylactic antibiotics were not routinely given to patients following upper abdominal radiotherapy (RT). A total of 193 (Kaplan and Meier, 1958) and compared using the log-rank test (Mantel, 1966 
RESULTS

Mortality and morbidity
The median follow-up was 11 years, the range was 0.7-18 years. Twenty patients were lost to follow-up; however, only five patients had a follow-up of less than 5 years. A total of 151 deaths have occurred and 460 (75%) patients were alive at the time of analysis. Overall, 365 of the surviving patients completed the patient questionnaire (79%) and 336 (73%) of the surviving patients' family doctors returned their questionnaires. We were able to supplement the information from the PMH records with information from the patient and/or the family doctor in 89% of cases. Ninety of the 151 deaths (60%) were either directly caused by Hodgkin's disease or were associated with active Hodgkin's disease at the time of death. Sixty-one deaths (40% of the total) occurred in patients with no evidence of active Hodgkin's disease (intercurrent deaths). Actuarial survival and cause-specific survival at 15 years for the whole group was 70.1% and 82.3% respectively (Figure 1 ). The causes of death are shown in Table 2 . After Hodgkin's disease, the major causes of mortality were second malignant neoplasms and ischaemic heart disease and/or cardiac failure ( Table 2 ). The intercurrent death rate among patients treated with XRT alone did not differ significantly from that of patients exposed to both chemotherapy and radiation therapy (P = 0.58). Figure 1 Survival and cause-specific survival for all patients. -0-,
Second malignant neoplasms
Excluding non-melanomatous skin cancer, 37 patients developed a second malignant neoplasm (SMN), and in 20 SMN was the cause of death. The actuarial rate of SMNs was 9.7% (13% including non-melanomatous skin cancer) at 15 years ( Figure 2 ). The acute leukaemia actuarial rate was 1.13% at 15 years, for non-Hodgkin's lymphoma it was 1.64% and for other solid neoplasms 6.93%. A list of first SMNs is given in Table 3 . The risks of developing SMN did not differ significantly between the treatment groups, radiation alone, radiation and salvage chemotherapy or CMT (P = 0.4). The observed number of second malignancies was 37 (three patients developed a third malignancy) compared with an expected incidence of 16.5 in the age-matched population of Ontario for the same time period, giving a relative risk (RR) of 2.24 (95% confidence interval 1.57-3.08) and an absolute excess risk per Table  4 . Six women developed breast cancer and all but one were less than 30 at the time of treatment of Hodgkin's disease. The median age at treatment was 25.5 (range 19-43), the median interval to the development of breast cancer was 10 years. One woman who was 43 at the time of her treatment for Hodgkin's disease developed breast cancer 3 years later. Only 38 patients had a splenectomy; therefore, the effect of splenectomy on the risk of second malignancy could not be assessed. However, the spleen was irradiated in 275 patients with a 15-year actuarial risk of second malignancy of 10% compared with 15% in 349 patients who did not have splenic irradiation (P = 0.1); there was no difference in length of follow-up between the two groups. By Cox proportional hazard model analysis for relative risk of second malignancy increasing age IHD, ischaemic heart disease; COPD, chronic obstructive pulmonary disease.
(30 years old at time of diagnosis) was a significant factor (RR 2.1:1, P = 0.035), but not gender, treatment modality or splenic radiation.
Cardiac disease
A total of 50 patients, without a prior history of heart disease, developed some form of cardiac morbidity after treatment for Hodgkin's disease. There were 11 deaths attributed to cardiac disease. The various forms of cardiac disease that arose are listed in Table 3 . The actuarial risk of heart disease was 11% at 15 years, 13% for those treated by XRT alone and 7% for the CMT group. The actuarial incidence of heart disease occurring in patients whose mediastinum was irradiated (10% at 15 years) was compared with those who had no mediastinal radiation (12% at 15 years, P = 0.15). The patients who had no mediastinal RT were older at diagnosis than those who had mediastinal irradiation (mean age 39 vs 33 years, P = 0.0001). By Cox proportional hazard model the only factors significant for increased risk of cardiac disease were male gender (P = 0.02) and older age (P = 0.0001). Mediastinal radiation was not a significant factor (P = 0.5). We were unable to obtain data for the incidence of heart disease for Ontario. However, age, gender and calendar year data were available on the incidence of myocardial infarction mortality for Ontario for 1973-84. The observed incidence was 9, expected 5.8 (RR 1.55, 95% confidence limits 0.71-2.95, chi-square P = 0.18, Table 4 , AR 5.4).
Respiratory disease Table 3 outlines the incidence of respiratory disease. There were no deaths from respiratory disease in the CMT group. In the RT alone group there were three deaths from pneumonitis or pulmonary fibrosis and one post-operative complication death after surgical repair of tracheal stenosis that occurred following emergency tracheostomy at diagnosis of Hodgkin's disease. One patient in the CMT group developed non-fatal adult respiratory distress syndrome after high-dose therapy with autologous bone marrow transplantation. There was no increase in pulmonary disease with the addition of chemotherapy.
Herpes zoster
A total of 101 patients (16.5%) developed a herpes zoster infection, including ten patients who had more than one episode, and six who developed generalized herpes zoster infection. There were no fatalities. The median time to development of zoster was 1.7 years (0.1-17.1). There was a significant difference in actuarial zoster rate between those treated by XRT alone (15% at 15 years) and those exposed to both XRT and chemotherapy (27% at 15 years, P = 0.001).
Thyroid disease
A total of 545 patients had radiation to their neck; abnormalities of the thyroid gland or thyroid function were documented in 93 (17%). Three categories of thyroid disease were defined: hyperthyroidism in eight patients (1.5%), hypothyroidism in 77 patients (14.1%) and benign thyroid nodules in eight patients (1.5%). For the purpose of this study hypothyroidism was defined as patients requiring thyroid replacement therapy. During the time period of the study there was no standard for when thyroid replacement therapy was started. No cases of thyroid cancer were observed. of 117 who had XRT alone and nine (18.4%) of 49 who had CMT stated they had not, but overall 143 (85.6%) stated that they had. Sixteen of 170 (9.4%) respondents stated that they had sought medical advice for infertility.
Menstruation
A total of 148 of the 170 female respondents were premenopausal at the time of their Hodgkin's treatment. In 21 women (ten after XRT and 11 after CMT) periods stopped and never restarted; in 22 women (13 after XRT, nine after CMT) periods stopped and restarted. The interval between stopping and restarting was 2-60 months (median 4.5 months).
Male fertility
A total of 191 men responded to the questionnaire items regarding fertility, and of these 57 had fathered 112 pregnancies. Thirty-eight men fathered pregnancies followed XRT (out of 100 respondents) five following XRT and salvage chemotherapy (out of 29) and 13 (out of 59) followed CMT, and one followed chemotherapy alone (out of three). Of men who received MOPP or MOPP-like chemotherapy ten fathered pregnancies after three or fewer courses (out of 47 respondents) and three (out of 12) who had four or more courses. A total of 147 men indicated that they were as successful as they wished in becoming a father. Twenty-eight (22%) of 127 who had XRT alone, one of three who had chemotherapy alone and 16 (28%) of 57 who had CMT stated that they had not. Forty-three of the 192 (22.5%) respondents stated that they had sought medical advice for infertility. Tucker Cosset et al, 1991a; Henry-Amar, 1992; Swerdlow et al, 1992; Abrahamsen et al, 1993; Dietrich et al, 1994; van Leeuwen et al, 1994; Mauch et al, 1995; Bhatia et al, 1996) . All studies showed a significant increased risk of second malignancies, in particular for acute leukaemia, non-Hodgkin's lymphoma and solid tumours. The relative risks of non-Hodgkin's lymphoma and leukaemia are considerably higher than for solid cancers because of a relative rarity of non-Hodgkin's lymphoma (NHL) and leukaemia compared with solid cancers. The Late Effects Study Groups (Bhatia et al, 1996) differs from the other studies as all patients entered were under the age of 16 at the time of treatment for Hodgkin's disease. Several reports (Hancock et al, 1988; Rodriquez et al, 1993; Biti et al, 1994; Dietrich et al, 1994; van Leeuwen et al, 1994) indicated that age greater than 40 at the time of diagnosis was associated with an increased risk of second maligancies. Although the AR increased with age, because malignancy is more common with increasing age, the relative risk of developing a second malignancy was greater in younger patients in this study, as has been reported by others (Henry-Amar, 1992; Swerdlow et al, 1992) . Splenectomy has been reported as a risk factor for second malignancy in some studies (van Leeuwen et al, 1994) but not others (Valagussa et al, 1986; Swerdlow et al, 1993) . The IDHD reported a relative risk of 1.3 for development of acute leukaemia (P < 0.05) and 1.4 for non-Hodgkin's lymphoma (P < 0.1). Dietrich et al (1994) , found that splenic irradiation as well as splenectomy was associated with an increased risk of development of second malignancy. We did not find a similar effect.
Effects of treatment on socioeconomic factors Marriage
An increased risk of myocardial infarction has been reported following mediastinal radiation (Cosset et al, 1991a,b) . Boivin et al (1992) reported an increased risk of mycoardial death at 5 years after radiation that persisted for 10 years or more, but was seen only in an early cohort of patients and not observed in the later cohort, treated by more modem radiotherapy techniques. Mauch et al (1995) reported a significantly increased cardiac mortality (RR 2.2, ). In the current study there was an increased risk of death from myocardial infarction but it was not statistically significant (RR 1.5, CI 0.7-3.0). It is possible that the absence of an increased RR of death from myocardial infarction relates to the lower RT dose to the mediastinum and smaller RT fraction size (35 Gy in 1.75-Gy fractions) than is described by most of the other series. However, in the series reported from Stanford (Hancock et al, 1993) , a persistent increased risk of myocardial infarction mortality was observed even after subcarinal blocking was introduced. The limited patient numbers and the relatively short length of follow-up in the current study may also contribute to the failure to find an increased risk of death from myocardial infarction.
Long-term pulmonary toxicity was difficult to assess by the questionnaire. It was difficult to exclude pre-existing pulmonary disease and difficult to differentiate between pneumonitis and pulmonary fibrosis. Accordingly, these were grouped together. Eight patients who were treated by radiation alone developed pneumonitis or pulmonary fibrosis and in three of these patients it was fatal; one patient had mediastinal reirradiation and another patient, who also developed radiation hepatitis, received standard mantle radiation to a dose of 35 Gy in 20 fractions and upper abdominal radiation with alternate fields per day. In comparison with the 3.75% incidence of pneumonitis in the current study, Tarbell et al Herpes zoster infection may develop within 2 years of treatment for Hodgkin's disease in 15-20% of patients (Hoppe, 1990) . In a multi-institutional study of 717 patients with Hodgkin's disease (Guinee et al, 1985) , the incidence was related to treatment intensity (11% for radiation alone and 27.5% for CMT) reflecting the findings of this study, in which the 15-year actuarial incidence was lower for radiation alone than for CMT. The study by Guinee et al(1983) found no influence on the attack rate of infections for stage, histology or splenectomy.
Many of the reports on thyroid function define hypothyroidism biochemically so that any patient with a raised thyroid-stimulating hormone (TSH) above the normal range is considered to have hypothyroidism. The rate of hypothyroidism in the current study is lower than that reported by other (Tarbell et al, 1990; Hancock et al, 1991; Peerboom et al, 1992 ) and could be due to the short followup or lower dose of radiation to the neck, or related to the differences in definitions of hypothyroidism. The Stanford series (Hancock et al, 1991) reported a higher risk of hypothyroidism in patients treated at a young age, which increased with length of follow-up and dose of radiation given. In the current study there were eight cases of Graves' disease, a high number, given the size of the study. Hancock et al (1991) reported an increased risk of Graves' disease of 7.2-20.4. Unlike Stanford, or the IDHD data, there were no thyroid cancers observed in our cohort.
That partners of male patients following treatment for Hodgkins have a lower frequency of pregnancy than female patients and that more men felt that they had been less successful in fathering pregnancies than they had wished and sought more medical advice with regards to fertility is in keeping with other reports (Aisner et al, 1993) . Chapman et al (1981) and others (e.g. Viviani et al, 1991) reported that sperm counts may be reduced before treatment. It is therefore uncertain whether the reduction in fertility is related to the disease rather than the treatment. In the current study however, the reduction in numbers of wanted pregnancies tended to be higher in those treated with combined modality treatment than radiation alone, suggesting that the treatment was a relevant factor. Whether this effect will be observed in those receiving ABVD rather than MOPP remains to be seen.
Despite differences in allocation of modalities of treatment, stages of disease and types of questions posed, several reports including this study have demonstrated restriction in physical functioning, lower perceived overall health, less satisfaction with sexual life, marital difficulties, difficulty in obtaining financial loans and life insurance, and more health-related unemployment limitations in patients treated for Hodgkin's disease (Fobair et al, 1986; Komblith et al, 1992a, b; Valagussa et al, 1992; van Tulder et al, 1994) .
This study, in keeping with others, has documented an increase risk in second maliganancy following treatment for Hodgkin's disease. We did not show a significantly increased risk of cardiac disease. This may be related to the lower RT dose compared with most series, or to the small patient numbers and the short followup of this study. Change in chemotherapy practice, e.g. the increased use of ABVD, could affect the incidence of both cardiac and pulmonary disease with more prolonged follow-up. Changing combination chemotherapy regimens may, however, be associated with a reduction in the incidence of second malignancies, certainly reduced incidence of leukaemia and possibly reduced frequency of problems with fertility. In the meantime, care should continue to be given to optimize practice by the use of good radiotherapy techniques such as two fractions a day and keeping the total dose and fraction size to as small a dose as possible. This study has also demonstrated the psychological, social, financial and sexual problems that occur in patients following treatment for early Hodgkin's disease. It is difficult to know how much is related to treatment and how much is related to the disease itself. However, it seems unlikely that current changes in treatment management will have a profound impact on these deleterious effects. This study demonstrated the importance of careful follow-up after treatment for Hodgkin's disease. Consideration should be given to screening for the more common problems and counselling when necessary. 
